Cassava Sciences Inc vs SPDR Gold Trust — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while SPDR Gold Trust trades at $364.85. The key difference: SPDR Gold Trust is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | GLD | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $495.90 |
52-Week Low | $1.09 | $300.96 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
GLD (SPDR Gold Shares ETF) trades at $365.75, down 1.72% amid bearish technical signals with 14 sell indicators. The ETF tracks physical gold prices, currently facing pressure from stabilizing dollar and rate-hike expectations. Recent economic data shows mixed signals with cooling inflation but strong labor market data weighing on gold prices. The fund provides direct exposure to gold bullion with lower volatility compared to mining stocks.
Gold's near-term outlook faces headwinds from potential Fed rate policy and dollar strength, though geopolitical tensions and central bank accumulation provide support. The technical picture suggests consolidation near key support levels with bearish momentum indicators. Investors should monitor Fed policy signals and inflation data for directional catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →